PTC Therapeutics's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2022 was $-1.78.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2022 was $-7.38.
PTC Therapeutics's EPS (Diluted) for the
three
months ended in Mar. 2022 was $-1.78.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-7.38.
PTC Therapeutics's EPS without NRI for the
three
months ended in Mar. 2022 was $-1.78.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2022 was -7.38.
During the past 3 years, the average EPS without NRIGrowth Rate was -39.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -21.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 11 years, PTC Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 18.40% per year. The lowest was -48.70% per year. And the median was 3.10% per year.
PTC Therapeutics EPS (Basic) Historical Data
The historical data trend for PTC Therapeutics's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
PTC Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EPS (Basic)
-2.02
-2.75
-4.27
-6.64
-7.43
PTC Therapeutics Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
EPS (Basic)
-1.83
-1.68
-1.89
-2.03
-1.78
PTC Therapeutics EPS (Basic) Calculation
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
PTC Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
PTC Therapeutics EPS (Basic) Related Terms
Thank you for viewing the detailed overview of PTC Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.11(0.28%) Volume: 250,291 12:14PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 
